⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ACAD News
Acadia Pharmaceuticals Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
accessnewswire.com
ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
accessnewswire.com
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
businesswire.com
ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
prnewswire.com
ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
prnewswire.com
ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
prnewswire.com
ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
prnewswire.com
ACAD
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders ®
businesswire.com
ACAD
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
businesswire.com
ACAD
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE ® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
businesswire.com
ACAD